Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NTRK1-pY674/pY675, PTPN6, and TP53 expression was assessed in 98 neuroblastoma samples by immunohistochemistry.
|
30594749 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
|
30664963 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study evaluated the effect of ethanolic extract of <i>Nardostachys jatamansi</i> roots (NJ<sub>et</sub>) on MYCN mediated regulation of expression of MDM2 and p53 proteins in neuroblastoma cell lines, IMR-32 and SK-N-MC.
|
28216878 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was previously reported that juniper extract (JE) affects p53 activity, cellular stress, and gene expression induced cell death in human neuroblastoma cells.
|
31027321 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that both TP53 Arg72Pro (CG/GG vs. CC: adjusted OR = 0.82, 95% CI = 0.69-0.98) and miR-34b/c rs4938723 (TC/CC vs. TT: adjusted OR = 0.64, 95% CI = 0.54-0.75) were associated with decreased neuroblastoma susceptibility.
|
31325764 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921 (RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models.
|
30536898 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Downregulation of PTHLH reduced MYCN expression and subsequently induced cell cycle arrest, senescence, and migration and invasion impairment in a MYCN-amplified, TP53-mutated neuroblastoma cell line.
|
31293052 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All-trans-retinoic acid (ATRA) treatment of MYCN/NCYM-amplified neuroblastoma CHP134 cells induced TAp63 and reduced p53 expressions, accompanied by downregulation of MYCN/NCYM expressions.
|
31427086 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although p53 is involved in PRIMA-1<sup>MET</sup>-mediated cell death, our results suggest that direct interaction with p53 has a limited role in neuroblastoma but rather acts through modulation of GSH levels.
|
30755224 |
2019 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this review, we summarize current knowledge about p53 pathway inactivation in childhood blastomas (specifically neuroblastoma, retinoblastoma and Wilms' tumor) through various upstream mechanisms.
|
30585860 |
2019 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This TP53 gene mutation may be pathogenic and lead to composite malignancies of ACC and neuroblastoma.
|
29746440 |
2019 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
|
30042831 |
2018 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of interest, TrkC was proposed to constrain tumor progression in neuroblastoma (NB), and we demonstrate in an avian model that TrkC tumor suppressor activity requires Hey1 and p53.
|
29750782 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These murine Trp53 wt and mutant TH-MYCN cell lines are useful syngeneic, immunocompetent neuroblastoma models, the former to test p53-dependent therapies in combination with immunotherapies, such as anti-GD2, and the latter as models of chemoresistant relapsed neuroblastoma when aberrations in the p53 pathway are more common.
|
29393340 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Introduction of miR-193b mimics into nine neuroblastoma cell lines with distinct genetic characteristics significantly reduces cell growth <i>in vitro</i> independent of risk factors such as p53 functionality or <i>MYCN</i> amplification.
|
29719597 |
2018 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that etoposide treatment induced significant and time-dependent increase of P53, which could be blocked by pre-treatment with BDNF, and knockdown P53 by transfecting siRNA attenuated etoposide-induced TrkB-expressing NB cell death.
|
29959561 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, both the impaired production of reactive oxygen species (ROS) in some NB cell lines and the transient p53 stabilization in response to our genotoxic drugs under our experimental conditions could contribute to inefficient induction of activating ligands.
|
29805983 |
2018 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Survival rates were lowest for neuroblastoma patients whose tumors harbored telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations.
|
30523111 |
2018 |
Childhood Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed 80 AVCs for the prognostic value of mutations of kirsten rat sarcoma (KRAS), neuroblastoma RAS (NRAS), B rapidly accelerated fibrosarcoma (BRAF), TP53, and 4 membrane erythroblastosis oncogene B (ERBB) receptor tyrosine kinases (EGFR-ERBB1, HER2-ERBB2, HER3-ERBB3, HER4-ERBB4) amenable to pharmacological inhibition.
|
27611608 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these observations, we suggest that PGEA-AN modulates P53 system which further leads to the death of the neuroblastoma cells with no effect on renal system in vivo owing it to be a future prospect for development of anticancer moiety against neuroblastoma.
|
29644528 |
2018 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we tested the hypothesis that MYCN amplification alters p53 transcriptional activity in neuroblastoma.
|
29755654 |
2018 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors.
|
30166519 |
2018 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fluoride induces apoptosis via inhibiting SIRT1 activity to activate mitochondrial p53 pathway in human neuroblastoma SH-SY5Y cells.
|
29609003 |
2018 |
Childhood Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of Bex genes by curcumin is associated with apoptosis and activation of p53 in N2a neuroblastoma cells.
|
28145533 |
2017 |
Childhood Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As we previously showed that fibroblast growth factor 1 (FGF1) inhibited p53-dependent apoptosis in neuron-like PC12 cells, we initiated the study of the interaction between the FGF1 and p53 pathways in neuroblastoma.
|
29048426 |
2017 |